Track topics on Twitter Track topics that are important to you
Congress is ready to fix the law meant to keep Americans safe from harmful chemicals.
Investors have hammered down shares of Sun Pharma after the world’s fifth-largest generic drug company issued a lower than expected sales forecast for this financial year.
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.
Troyer® Cheese Inc, under advice from its packaging facility concerning, CRANBERRY NUT DELIGHT MIX PREPACK, HONEY ISLAND CRUNCH MIX PREPACKAGED, PRETZELS PEANUT BUTTER PREPACKAGED, WALNUT HALVES/PIECES PREPACKAGED, SUNFLOWER SEEDS R&S PREPACKAGED AND SUNFLOWER SEEDS R&S BULK is recalling a limited number of products that have the potential to be contaminated with Listeria monocytogenes, an organ...
BioMarin Pharmaceutical took a $680 million gamble when it bought Prosensa in 2014 for its experimental Duchenne muscular dystrophy treatment. Drisapersen (Kydrisa) had already failed a Phase 3 trial, but BioMarin bet it could dig through the data and win FDA approval. It lost that bet, and now BioMarin (NASDAQ: BMRN) is pulling the plug […]
I have recently concluded that the term "best-of-breed LIS" has ceased to be useful as products like Epic's Beaker approach the functionality of competing LISs. Beaker still lacks a blood bank module which causes customers to seek one from another vendor. Epic has been assisted in its pursuit of BoB...
A new book shows how algorithmic thinking from computer science can solve very human problems
Distractions while operating a motor vehicle lead to 8 deaths and 1,161 injuries in the U.S. every single day.
Billionaire investor Carl Icahn took a stake in Allergan PLC and threw his support behind the drug company’s chief executive, Brent Saunders, in a departure from the activist’s usual playbook.
By Nicholas Wilcken, University of Sydney Treating breast cancer with a very high dose of chemotherapy doesn’t improve survival any more than if using a standard dose. A recent Cochrane review has put the final nail in the coffin of decades of research debunking the antiquated idea that, if only we could give a high […] The post More effective and less invasive: how breast cancer treatment...
From The Argus, Brighton | 31 May 2016 | Story by Siobhan Ryan. A TEACHING assistant struck down by a debilitating illness with no known cure is set to finish...
This piece is written by Thomas Ehrlich. He recently recovered from unexpected colon surgery and shares his experience here.
StemCells (NASDAQ: STEM) has decided to close up shop after its most advanced therapy didn’t do enough in a Phase 2 trial to improve people with spinal cord injuries. The one-time stem cell pioneer will wind down operations with $5.5 million in the bank, as of May 31, it said in a statement this morning. […]
As part of its planned overhaul of the regulatory framework for medicines and medical devices, the New Zealand government says it intends to 'realize New Zealand's potential as a clinical trial destination' by updating the clinical trial regulations in line with international norms, and extending trial oversight to all therapeutic products.
The Food and Drug Administration rejected a drug application from Teva Pharmaceutical Industries Ltd., asking for more information on the effects of the drug that treats some symptoms of Huntington’s disease.
General Mills is collaborating with health officials to investigate an ongoing, multistate outbreak of E. coli O121 that may be potentially linked to Gold Medal flour, Wondra flour, and Signature Kitchens flour (sold in Safeway, Albertsons, Jewel, Shaws, Vons, United, Randalls, and Acme). Out of an abundance of caution, a voluntary recall is being made.
The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert. The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in th...
The Biosimilars Forum recently launched its educational initiative known as the “Partnership for Biosimilar Education and Access.” Throughout the development of this initiative, it became clear to the Forum membership that physicians have specific educational needs that extend far beyond policy.
BioMarin Pharmaceutical Inc. will abandon development of an experimental treatment for Duchenne muscular dystrophy and three other related products.
With OCA approved for primary biliary cholangitis, Intercept anticipates a potentially slow ramp of sales, but has priced product at $69,350 a year based on need in second-line treatment and in anticipation of survival benefit data.
FDA's complete response letter for deutetrabenazine for treatment of chorea associated Huntington disease does not request additional clinical trials, and Teva said a filing timeline for tardive dyskinesia remains unchanged.
Every guy needs to admit this one honest truth: Feeling that you’re getting old sucks, no matter what your age. We all look in the mirror every morning and judge ourselves on how we look. The numbers also don’t lie. According to the American Society of Plastic Surgeons, over 400,000 U.S. [...]